First Quadrant L P CA decreased its position in Zoetis Inc. (NYSE:ZTS) by 0.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 499,444 shares of the company’s stock after selling 4,122 shares during the period. Zoetis makes up 0.6% of First Quadrant L P CA’s portfolio, making the stock its 25th largest position. First Quadrant L P CA owned 0.10% of Zoetis worth $31,155,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of ZTS. Assetmark Inc. raised its stake in shares of Zoetis by 4.6% in the first quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock worth $102,000 after buying an additional 85 shares during the period. Guardian Life Insurance Co. of America raised its stake in shares of Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock worth $102,000 after buying an additional 13 shares during the period. Point72 Asia Hong Kong Ltd acquired a new stake in shares of Zoetis during the first quarter worth about $111,000. Advisory Services Network LLC acquired a new stake in shares of Zoetis during the first quarter worth about $112,000. Finally, First Interstate Bank raised its stake in shares of Zoetis by 3.5% in the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock worth $120,000 after buying an additional 76 shares during the period. Institutional investors own 94.51% of the company’s stock.
Shares of Zoetis Inc. (ZTS) traded down 0.02% during trading on Friday, reaching $59.73. The company had a trading volume of 2,285,863 shares. The firm has a 50-day moving average price of $62.20 and a 200-day moving average price of $58.00. Zoetis Inc. has a 52-week low of $46.86 and a 52-week high of $63.85. The company has a market capitalization of $29.21 billion, a P/E ratio of 33.76 and a beta of 1.02.
Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the consensus estimate of $0.53. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The business’s revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.49 EPS. On average, analysts predict that Zoetis Inc. will post $2.34 EPS for the current fiscal year.
ZTS has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $67.00 price target on the stock in a research note on Wednesday, May 10th. Jefferies Group LLC upped their target price on shares of Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, May 9th. BMO Capital Markets restated a “buy” rating and set a $60.00 target price on shares of Zoetis in a research note on Thursday, May 4th. Argus restated a “buy” rating and set a $69.00 target price (up from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. Finally, CL King started coverage on shares of Zoetis in a research note on Friday, May 26th. They set a “buy” rating and a $71.00 target price on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Zoetis has an average rating of “Buy” and a consensus target price of $64.78.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.